Adults with chronic multisite pain had poorer psychosocial outcomes than those with single-site pain, but kinesiophobia levels were high in both groups.

The Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain.

Disease activity during pregnancy remained stable among the majority of women with RA or SpA, though relapses requiring treatment intensification were not uncommon.

Patients who are older and those who are of Hispanic ethnicity are more likely to demonstrate post-burn subjective visual complaints.

HealthDay News — For patients with interstitial cystitis (IC), transurethral fulguration (TUF) is effective for alleviating pelvic pain, according to a study published online April 3 in Neurourology ...

A new initiative called "Generation Gold Standard" was announced to develop next-generation, universal vaccines using a beta-propiolactone-inactivated, whole-virus platform.

Robert F. Kennedy Jr plans to change how vaccines are tested in the US, a decision that could impact how quickly and widely vaccines are made available.

Despite medical innovations, maternal mortality rates in the US remain high, especially compared with those of similarly ...

The FDA has granted marketing authorization to CT-132 for the preventive treatment of episodic migraine in patients aged 18 years and older.

Patients with acute episodic migraine consistently prioritize pain relief over other treatment attributes such as route of administration, adverse outcomes, and costs, according to study results ...

Mesenchymal precursor cells plus hyaluronic acid significantly reduced chronic low back pain due to degenerative disc disease.

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.